BioSpace News Archive

INOVIO’s Pan-SARS-CoV-2 vaccine candidate INO-4802 is not matched to a single variant, unlike other variant vaccines in development; INO-4802 could potentially offer broader immune responses [12-May-2021] PLYMOUTH MEETING, Pa. , May 12, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology com

Inscopix Inc. a leading neurotechnology company in California that empowers breakthroughs in brain science announced the signing of a distribution agreement with Animalab, a prominent neuroscience distributor in Poland, Czech Republic, Hungary, Slovakia, Latvia, Lithuania, Estonia, Croatia and Slovenia.

Sequans Communications S.A. has joined forces with AmericanPharma Technologies and is providing the cellular IoT connectivity solution for AmericanPharma Tech’s PharmaWatch™ vaccine monitoring system that is currently protecting Covid-19 vaccine shipments and storage around the country.

ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to accelerate development of AAGP® (PKX-001) in ocular conditions, specifically Dry Eye Disease and Wet and Dry forms of Age-related Macular Degeneration.

VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI’s Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases

CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and rare cancers in China and globally, announced that James Xue, Ph.D., Founder, Chairman has been invited to serve as a Termeer Foundation Mentor by the Termeer Foundation.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on its AlloCAR T platform during a virtual CD19 Forum on May 19, 2021 at 2:30 PM Pacific Time/5:30 PM Eastern Time.

IntelGenx Corp. announced that it has entered into a second feasibility agreement with ATAI Life Sciences AG

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced the pricing of its public offering of 13,333,333 shares of its common stock at a price to the public of $2.25 per share.

As the focus on the COVID-19 pandemic shifts to raising the number of vaccinated people around the world, U.S. researchers, funded by the NIH, are undertaking a large new clinical trial to find effective treatments, in the belief that while controllable, SARS-Cov-2 and its variants will continue to cause endemic disease in many parts of the world.